155 related articles for article (PubMed ID: 34254287)
1. Blinatumomab for paediatric mixed phenotype acute leukaemia.
Bartram J; Balasch-Carulla M; Bhojaraja S; Adams S; Cheng D; Inglott S; Kulkarni N; Mahendrayogam A; O'Connor O; Pavasovic V; Vora A
Br J Haematol; 2021 Oct; 195(2):289-292. PubMed ID: 34254287
[No Abstract] [Full Text] [Related]
2. MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL.
Yang W; Tran P; Khan Z; Rezk S; O'Brien S
Leuk Lymphoma; 2017 Jun; 58(6):1498-1501. PubMed ID: 27774846
[No Abstract] [Full Text] [Related]
3. Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.
El Chaer F; Ali OM; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Wong J; Yared JA; Griffiths EA; Emadi A
Am J Hematol; 2019 Jan; 94(1):E7-E8. PubMed ID: 30328137
[No Abstract] [Full Text] [Related]
4. Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
Popov A; Fominikh V; Mikhailova E; Shelikhova L; Tsaur G; Abugova Y; Zerkalenkova E; Olshanskaya Y; Balashov D; Novichkova G; Maschan A; Miakova N
Br J Haematol; 2021 Jul; 194(1):174-178. PubMed ID: 33843056
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in
Wölfl M; Rasche M; Eyrich M; Schmid R; Reinhardt D; Schlegel PG
Blood Adv; 2018 Jun; 2(12):1382-1385. PubMed ID: 29898879
[TBL] [Abstract][Full Text] [Related]
6. Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23);
Du J; Chisholm KM; Tsuchiya K; Leger K; Lee BM; Rutledge JC; Paschal CR; Summers C; Xu M
Pediatr Dev Pathol; 2021; 24(4):378-382. PubMed ID: 33749383
[TBL] [Abstract][Full Text] [Related]
7. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.
Zoghbi A; Zur Stadt U; Winkler B; Müller I; Escherich G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453885
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
[No Abstract] [Full Text] [Related]
9. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ
Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
12. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
14. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
15. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
[TBL] [Abstract][Full Text] [Related]
16. A closer look at blinatumomab.
Mattison RJ
Clin Adv Hematol Oncol; 2018 Jun; 16(6):412-414. PubMed ID: 30067611
[TBL] [Abstract][Full Text] [Related]
17. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Gökbuget N; Zugmaier G; Klinger M; Kufer P; Stelljes M; Viardot A; Horst HA; Neumann S; Brüggemann M; Ottmann OG; Burmeister T; Wessiepe D; Topp MS; Bargou R
Haematologica; 2017 Apr; 102(4):e132-e135. PubMed ID: 28082340
[No Abstract] [Full Text] [Related]
18. Aggressive MLL gene rearranged CD7+ CD56+ myeloid / natural killer cell precursor acute leukaemia with extramedullary relapse in the uterus and breast.
Soon G; Lee SY; Wang S
Pathology; 2015 Oct; 47(6):588-91. PubMed ID: 26308138
[No Abstract] [Full Text] [Related]
19. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
Jen EY; Xu Q; Schetter A; Przepiorka D; Shen YL; Roscoe D; Sridhara R; Deisseroth A; Philip R; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jan; 25(2):473-477. PubMed ID: 30254079
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia.
Sarkar S; Rav E; Stitzlein L; Gibson A; McCall D; Nunez C; Roth M; Ragoonanan D; Connors J; Herzog CE; Cuglievan B; Garcia MB
Pediatr Blood Cancer; 2024 Jun; 71(6):e30964. PubMed ID: 38514796
[No Abstract] [Full Text] [Related]
[Next] [New Search]
